logo-loader
viewCytoDyn Inc.

CytoDyn says coronavirus patients treated with leronlimab show initial improvements after three days

Leronlimab has been administered to 10 severely ill coronavirus patients in the New York City area

Person using a ventilator
CytoDyn is enrolling patients in a Phase 2 trial for coronavirus patients with mild-to-moderate indications and a Phase 2b/3 trial for patients who are critically ill

CytoDyn Inc (OTCQB:CYDY) announced Thursday that eight severe coronavirus (COVID-19) patients being treated with its drug leronlimab have shown a significant improvement after three days in several important biologic markers. 

Initial patient test data has shown improvement in cytokines — proteins released by the immune system that can cause inflammation in high quantities  — and a more normal ratio of helper T cells to killer T cells in the immune system, known as the CD4/CD8 ratio.

Leronlimab has been administered to 10 severely ill coronavirus patients in the New York City area under an emergency Investigational New Drug application granted by the US Food & Drug Administration (FDA).

READ: CytoDyn files second clinical trial protocol to treat severely ill coronavirus patients with lernlimab

CytoDyn is also enrolling patients in a Phase 2 trial for coronavirus patients with mild-to-moderate indications and a Phase 2b/3 trial for patients who are critically ill.

Bruce Patterson, the CEO of CytoDyn’s diagnostic partner and advisor IncellDX, is impressed with the results so far.

“We are very pleased with our most recent laboratory data for patients treated with leronlimab for COVID-19 infection,” Patterson said in a statement.

“We continue to see increases in the profoundly decreased CD8 T-lymphocyte percentages by day three, normalization of CD4/CD8 ratios and resolving cytokine production including reduced IL-6 correlating with patient improvement. The current data suggests a trend toward the restoration of immune function and mitigation of the cytokine storm. This is consistent with prior laboratory results in the first four patients treated for COVID-19 with leronlimab.”

Seeing leronlimab’s initial success, CEO Nader Pourhassan and his team are also examining how best to distribute the drug across the country.

“As leronlimab continues to provide hope for many patients, our management team is focused to ensure we can distribute the drug across the country in a timely fashion,” Pourhassan said. “These results, although anecdotal, appear to be very promising.”

In addition to its use as a potential coronavirus treatment, leronlimab has other therapeutic indications as a treatment for HIV and certain breast cancers.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: CytoDyn Inc.

Price: 3.1 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.49 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn to work with Mexican National Institutes of Health to treat...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotech has plans to work with the Mexican National Institutes of Health on a trial of leronlimab for severe coronavirus patients in the country. Pourhassan says the initial trial is expected to include about 30 patients. After...

4 days, 13 hours ago

2 min read